Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Adagene ( (ADAG) ) has shared an update.
Adagene Inc. announced updated clinical data from their Phase 1b/2 study of ADG126 combined with pembrolizumab, demonstrating a 33% overall response rate in colorectal cancer patients at the ASCO GI Cancers Symposium. The study highlights the potential of ADG126 as a safe and effective treatment, with no severe treatment-related adverse events observed. The promising results may enhance Adagene’s industry positioning, allowing for broader patient inclusion in future studies and potentially marking ADG126 as a best-in-class CTLA-4 inhibitor.
More about Adagene
Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies. Utilizing computational biology and artificial intelligence, Adagene designs antibodies to address unmet patient needs globally. The company’s proprietary Dynamic Precision Library platform, featuring technologies like SAFEbody, enables precision in targeting tumor-specific cells, while minimizing toxicity in healthy tissues. Their lead program, ADG126, is a masked anti-CTLA-4 antibody aimed at treating metastatic microsatellite-stable colorectal cancer.
YTD Price Performance: -6.31%
Average Trading Volume: 98,852
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $85.44M
For an in-depth examination of ADAG stock, go to TipRanks’ Stock Analysis page.
